Annual Report 2010/11 - Sonova
Annual Report 2010/11 - Sonova Annual Report 2010/11 - Sonova
68 COMPEnSATIOn TO MEMBErS Of THE BOArD Of DIrECTOrS Total compensation to the Board of Directors consists of a fixed fee, attendance fees, expenses, social benefits (employer’s contribution), and participation in the Executive Equity Award Plan (solely with entitlement to receive options, warrants, WArs and SArs). The following table shows the compensation for the individual members of the Board of Directors in the year under review and in the previous year: in CHf 2010/11 fixed fee Attendance fee/expenses 1) Social benefits (employer’s contribution) 2) Total cash compensation Value of warrants 3) number of warrants 3) granted Total compensation robert f. Spoerry, Chairman4) 120,000 27,500 152,806 300,306 240,300 250,000 540,606 William D. Dearstyne, Vice-Chairman 120,000 30,000 320,122 470,122 240,300 250,0005) 710,422 Andy rihs, Member4) 120,000 31,000 188,790 339,790 240,300 250,000 580,090 Heliane Canepa, Member 120,000 27,000 61,484 208,484 240,300 250,000 448,784 Dr. Michael Jacobi, Member 120,000 23,500 63,758 207,258 240,300 250,000 447,558 Anssi Vanjoki, Member 120,000 15,500 25,715 161,215 240,300 250,000 401,515 ronald van der Vis, Member 120,000 14,500 25,539 160,039 240,300 250,000 400,339 John J. Zei, Member6) 90,000 16,500 17,713 124,213 240,300 250,0005) 364,513 Total 930,000 185,500 855,927 1,971,427 1,922,400 2,000,000 3,893,827 1) Attendance fees and expenses are based on the number of attended meetings of each member of the Board of Directors. 2) Including social security contributions on the tax value of options/WArs/SArs exercised during the reporting period. 3) Exercise ratio between warrants and options: 25:1 (see also note 30 in the consolidated financial statements). 4) robert f. Spoerry took over the position as Chairman of the Board of Directors from Andy rihs in March 2011. 5) WArs (WArs grant the right to participate in the appreciation of the Sonova shares without issuance of shares). 6) new member of the Board of Directors since June 2010. Dr. Valentin Chapero rueda received no compensation for his mandate as a member of the Board of Directors due to his mandate as CEO. in CHf 2009/10 fixed fee Attendance fee/expenses 1) Social benefits (employer’s contribution) 2) Total cash compensation Value of warrants 3) number of warrants 3) granted Total compensation Andy rihs, Chairman 120,000 28,000 146,705 294,705 275,725 250,000 570,430 William D. Dearstyne, Vice-Chairman 60,000 28,000 11,211 99,211 275,725 250,0004) 374,936 Heliane Canepa, Member 60,000 23,000 98,225 181,225 275,725 250,000 456,950 Dr. Michael Jacobi, Member 60,000 24,500 259,414 343,914 275,725 250,000 619,639 robert f. Spoerry, Member 60,000 22,500 204,642 287,142 275,725 250,000 562,867 Anssi Vanjoki, Member 45,000 12,500 10,456 67,956 275,725 250,000 343,681 ronald van der Vis, Member 45,000 12,000 10,456 67,456 275,725 250,000 343,181 Total 450,000 150,500 741,109 1,341,609 1,930,075 1,750,000 3,271,684 1) Attendance fees and expenses are based on the number of attended meetings of each member of the Board of Directors. 2) Including social security contributions on the tax value of options/WArs/SArs exercised during the reporting period. 3) Exercise ratio between warrants and options: 25:1 (see also note 30 in the consolidated financial statements). 4) WArs (WArs grant the right to participate in the appreciation of the Sonova shares without issuance of shares). Dr. Valentin Chapero rueda received no compensation for his mandate as a member of the Board of Directors due to his mandate as CEO.
COMPEnSATIOn TO MEMBErS Of THE MAnAGEMEnT BOArD COMPEnSATIOn rEPOrT Total compensation to the Management Board consists of a fixed and variable salary component, additional benefits, social benefits (employer’s contributions), and participation in the Executive Equity Award Plan (solely with entitlement to receive warrants/options). The following table shows the compensation for the CEO (highest compensation) and the other members of the Management Board in the year under review and in the previous year: in CHf 2010/11 fixed salary Variable salary 1) fringe benefits Social benefits (employer’s contribution) 2) Total cash compen- sation 1)/2) Value of warrants 3) number of warrants 3) granted Total compensation 2) Dr. Valentin Chapero rueda, CEO4) Other members of the Management 1,500,000 521,976 16,000 404,789 2,442,765 672,960 700,125 3,115,725 Board5) 2,396,409 1,008,930 162,315 687,055 4,254,709 3,616,515 3,762,500 7,871,224 Total 3,896,409 1,530,906 178,315 1,091,844 6,697,474 4,289,475 4,462,625 10,986,949 1) The variable salary will be paid out after the end of the reporting year. 2) Including social security contributions on the tax value of options/warrants exercised during the reporting period. 3) Exercise ratio between warrants and options: 25:1 (see also note 30 in the consolidated financial statements). 4) Dr. Valentin Chapero rueda was CEO until March 30, 2011. 5) Oliver Walker was a member of the Management Board until March 30, 2011, Cameron Hay until november 30, 2010. in CHf 2009/10 fixed salary Variable salary 1) fringe benefits Social benefits (employer’s contribution) 2) Total cash compen- sation 1)/2) Value of warrants 3) number of warrants 3) granted Total compensation 2) Dr. Valentin Chapero rueda, CEO Other members of the Management 1,185,597 1,866,830 16,000 439,010 3,507,437 3,507,437 Board4) 2,470,164 1,539,756 194,715 805,980 5,010,615 4,888,603 4,432,500 9,899,218 Total 3,655,761 3,406,586 210,715 1,244,990 8,518,052 4,888,603 4,432,500 13,406,655 1) The variable salary will be paid out after the end of the reporting year. 2) Including social security contributions on the tax value of options/warrants exercised during the reporting period. 3) Exercise ratio between warrants and options: 25:1 (see also note 30 in the consolidated financial statements). 4) Elmar Götz was member of the Management Board until January 2010. 69
- Page 21 and 22: THE HEARING INSTRUMENT MARKET - CON
- Page 23 and 24: THE PHONAK SPICE GENERATION - THE S
- Page 25 and 26: WIDE RANGE OF HEARING INSTRUMENTS T
- Page 27 and 28: LYRIC - THE “CONTACT LENS FOR THE
- Page 29 and 30: Sonova is investing heavily in the
- Page 31 and 32: Eight years later, Evelyn almost co
- Page 33 and 34: THE HEARING IMPLANTS SEGMENT In the
- Page 35 and 36: The considerable strategic importan
- Page 37 and 38: ABOUT ADVANCED BIONICS Advanced Bio
- Page 39 and 40: worKinG - and communicating safely
- Page 41 and 42: EMPLOYEES FOCUS ON PEOPLE One of th
- Page 43 and 44: ISO 9001:2000 and 13485:2003 certif
- Page 45 and 46: The key environmental data shown in
- Page 47 and 48: ENVIRONMENTAL MANAGEMENT AT THE ST
- Page 49 and 50: CAMBODIA - BETTER OPPORTUNITIES FOR
- Page 51 and 52: Better hearing - better success at
- Page 53 and 54: in critical moments. As a consequen
- Page 55 and 56: CrOSS-SHArEHOLDInGS Sonova Holding
- Page 57 and 58: BOArD Of DIrECTOrS The primary duty
- Page 59 and 60: Andy rihs Co-founder, non-executive
- Page 61 and 62: onald van der Vis non-executive mem
- Page 63 and 64: AuDIT COMMITTEE The members of the
- Page 65 and 66: Alexander Zschokke Interim CEO, GVP
- Page 67 and 68: Dr Hans Leysieffer GVP research & D
- Page 69 and 70: COmPenSatiOn and SharehOldingS - co
- Page 71: The shares/rSus have a blocking per
- Page 75 and 76: SHArEHOLDInGS Of MEMBErS Of THE BOA
- Page 77 and 78: The following table shows the detai
- Page 79 and 80: CHAnGES Of COnTrOL AnD DEfEnSE MEAS
- Page 81 and 82: COMPEnSATIOn rEPOrT inveStOrS at SO
- Page 83: develOPing SPeeCh CaPaBilitieS - mo
- Page 86 and 87: 82 Financial Review - setting the c
- Page 88 and 89: 84 SALES in CHF m EBITA in CHF m 1,
- Page 90 and 91: 86 SUBSTANTIAl INVESTMENTS IN INNoV
- Page 92 and 93: 88 AdVANCEd BIoNICS RESUMES SAlES I
- Page 94 and 95: 90 5 year key Figures (Consolidated
- Page 96 and 97: 92 Consolidated Income Statements 1
- Page 98 and 99: 94 Consolidated Cash Flow Statement
- Page 100 and 101: 96 NoTeS To THe CoNSoLIdATed FINANC
- Page 102 and 103: 98 INveSTMeNTS IN JoINT veNTuReS In
- Page 104 and 105: 100 LeASING Assets that are held un
- Page 106 and 107: 102 SeGMeNT RePoRTING operating seg
- Page 108 and 109: 104 3.5 derivative financial instru
- Page 110 and 111: 106 3.7 Restatement of prior year
- Page 112 and 113: 108 Consolidated Changes in Equity
- Page 114 and 115: 110 5. segment information segment
- Page 116 and 117: 112 6. other expenses, net 1,000 ch
- Page 118 and 119: 114 Deferred tax assets and (liabil
- Page 120 and 121: 116 11. cash and cash equivalents 1
COMPEnSATIOn TO MEMBErS Of THE MAnAGEMEnT BOArD<br />
COMPEnSATIOn rEPOrT<br />
Total compensation to the Management Board consists of a fixed and variable salary component, additional benefits, social<br />
benefits (employer’s contributions), and participation in the Executive Equity Award Plan (solely with entitlement to<br />
receive warrants/options).<br />
The following table shows the compensation for the CEO (highest compensation) and the other members of the Management<br />
Board in the year under review and in the previous year:<br />
in CHf <strong>2010</strong>/<strong>11</strong><br />
fixed<br />
salary<br />
Variable<br />
salary 1)<br />
fringe<br />
benefits<br />
Social benefits<br />
(employer’s<br />
contribution) 2)<br />
Total cash<br />
compen-<br />
sation 1)/2)<br />
Value of<br />
warrants 3)<br />
number of<br />
warrants 3)<br />
granted<br />
Total<br />
compensation<br />
2)<br />
Dr. Valentin Chapero<br />
rueda, CEO4) Other members of<br />
the Management<br />
1,500,000 521,976 16,000 404,789 2,442,765 672,960 700,125 3,<strong>11</strong>5,725<br />
Board5) 2,396,409 1,008,930 162,315 687,055 4,254,709 3,616,515 3,762,500 7,871,224<br />
Total 3,896,409 1,530,906 178,315 1,091,844 6,697,474 4,289,475 4,462,625 10,986,949<br />
1) The variable salary will be paid out after the end of the reporting year.<br />
2) Including social security contributions on the tax value of options/warrants exercised during the reporting period.<br />
3) Exercise ratio between warrants and options: 25:1 (see also note 30 in the consolidated financial statements).<br />
4) Dr. Valentin Chapero rueda was CEO until March 30, 20<strong>11</strong>.<br />
5) Oliver Walker was a member of the Management Board until March 30, 20<strong>11</strong>, Cameron Hay until november 30, <strong>2010</strong>.<br />
in CHf 2009/10<br />
fixed<br />
salary<br />
Variable<br />
salary 1)<br />
fringe<br />
benefits<br />
Social benefits<br />
(employer’s<br />
contribution) 2)<br />
Total cash<br />
compen-<br />
sation 1)/2)<br />
Value of<br />
warrants 3)<br />
number of<br />
warrants 3)<br />
granted<br />
Total<br />
compensation<br />
2)<br />
Dr. Valentin Chapero<br />
rueda, CEO<br />
Other members of<br />
the Management<br />
1,185,597 1,866,830 16,000 439,010 3,507,437 3,507,437<br />
Board4) 2,470,164 1,539,756 194,715 805,980 5,010,615 4,888,603 4,432,500 9,899,218<br />
Total 3,655,761 3,406,586 210,715 1,244,990 8,518,052 4,888,603 4,432,500 13,406,655<br />
1) The variable salary will be paid out after the end of the reporting year.<br />
2) Including social security contributions on the tax value of options/warrants exercised during the reporting period.<br />
3) Exercise ratio between warrants and options: 25:1 (see also note 30 in the consolidated financial statements).<br />
4) Elmar Götz was member of the Management Board until January <strong>2010</strong>.<br />
69
Change language